\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationCampus Cyber, Paris
ProgrammesThis event gathers European-wide innovators and practitioners. It focuses on connecting individuals who are actively seeking consortium partners and to bring their game-changing ideas and novel technologies to life, addressing the challenges outlined in Horizon Europe’s Civil Security for Society 2023-2024 Work Programme.
The event will feature top-level keynote speeches, expert panel discussions as well as ground-breaking pitch sessions. It will offer significant networking opportunities and information on Horizon Europe Security Calls.
The SMI2G brokerage event is organised by: The EARTO Working Group Security and Defence research, the SEREN network, EOS, IMG-S, ECSO, CMINE and is supported by the Ministère de l’Enseignement Supérieur et de la Recherche, Campus Cyber and ENLETS.
The event will be held in presence.
To register, check out the event page here.
For further information, please contact the organisers at enquiries@smi2g.eu
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
